Results 111 to 120 of about 238,162 (269)

Additional file 1: of Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimerâ s disease

open access: yes, 2019
Table S1. Proteins related to neuronally derived EVs of Alzheimerâ s disease patients (DOCX 95 kb)
Watson, Luke   +3 more
openaire   +1 more source

Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the relationship of subjective cognitive concerns (SCC) with biomarkers of Alzheimer's disease (AD), neurodegeneration, and Parkinson's disease (PD) and domain‐specific cognitive trajectories among cognitively unimpaired persons with de novo PD. Method Cognitively unimpaired participants with SCC (n = 294) and without SCC (
Francesca V. Lopez   +5 more
wiley   +1 more source

Proteomic analysis in Alzheimer’s disease and other dementias: a focus on sex-specific differences

open access: yesAlzheimer’s Research & Therapy
Background Fluid protein studies in cerebrospinal fluid (CSF) and plasma have provided important insights into neurodegenerative dementias; however, there is a limited investigation of sex-related differences and cross-biofluid relationships.
Aina Comas-Albertí   +20 more
doaj   +1 more source

Additional file 2: of Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimerâ s disease

open access: yes, 2016
BEATADStatisticalPlanFinal_1 3_20141209. (DOC 467 kb)
Cummings, Jeffrey   +9 more
openaire   +1 more source

Cerebrospinal Fluid Over Plasma Links Analytes to Cognitive Decline in Older Adults at Risk for Alzheimer's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify inflammatory analytes in cerebrospinal fluid (CSF) and plasma associated with cognitive decline in cognitively normal (CN) older adults at risk for Alzheimer's disease (AD). Methods In a longitudinal study of 118 CN older adults (65–80 years, 54% APOE ε4, 26% preclinical AD), 1331 CSF and 1501 plasma analytes were ...
Jagan A. Pillai   +13 more
wiley   +1 more source

Additional file 12: Table S3. of Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimerâ s disease model

open access: yes, 2017
List of the C3 cytokine array data. (PDF 24088 kb)
Liu, Yi-Ling   +5 more
openaire   +1 more source

Systemic Extracerebral Atherosclerotic Burden and Dementia Risk After Incident Stroke

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Stroke survivors are at increased risk of dementia, but clinically accessible markers of risk heterogeneity remain limited. Previous studies have largely examined atherosclerotic disease in individual vascular beds rather than the overall burden of systemic extracerebral atherosclerosis.
Zhexuan Yu   +4 more
wiley   +1 more source

Additional file 1: of Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimerâ s disease

open access: yes, 2017
Supplementary Experimental Procedures. Figure S1. The topological overlap matrix plot of the protein co-expression network constructed from the proteomics data from the autopsied brains in the MSBB cohort, along with the dendrogram showing the tree cutting process used to define modules (above). Figure S2.
McKenzie, Andrew   +21 more
openaire   +1 more source

Dynamic Changes in Serum Glial Fibrillary Acidic Protein Levels Predicts Early Neurological Deterioration After Intravenous Thrombolysis in Minor Stroke

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Minor strokes may be associated with early neurological deterioration (END) and disabilities. The objective was to investigate the role of serum glial fibrillary acidic protein (GFAP) levels in predicting END. Methods Data originated from a multicenter cohort study conducted prospectively.
Jie Zhou   +45 more
wiley   +1 more source

Additional file 1: of Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimerâ s disease

open access: yes, 2016
BexProtocol-Ver#2-8-1-12. (DOC 299 kb)
Cummings, Jeffrey   +9 more
openaire   +1 more source

Home - About - Disclaimer - Privacy